TrialThe lancet. HIV2018

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

Sharon Nachman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.